Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Personalis Inc (NQ: PSNL )

1.560 -0.010 (-0.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 454,171
Open 1.610
Bid (Size) 1.540 (28)
Ask (Size) 1.700 (16)
Prev. Close 1.570
Today's Range 1.560 - 1.709
52wk Range 0.8906 - 4.310
Shares Outstanding 48,518,901
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
From Personalis, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga

Performance

YTD
-22.39%
-22.39%
1 Month
+47.17%
+47.17%
3 Month
-3.70%
-3.70%
6 Month
-38.58%
-38.58%
1 Year
-44.88%
-44.88%

More News

Read More
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
From Personalis, Inc.
Via Business Wire
Personalis: Q3 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Earnings Outlook For Personalis
Via Benzinga
Personalis Reports Third Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
From Personalis, Inc.
Via Business Wire
Personalis to Announce Third Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
From Personalis, Inc.
Via Business Wire
Earnings Scheduled For November 7, 2023
Via Benzinga
Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023
From Personalis, Inc.
Via Business Wire
Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance
From Personalis, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
From Personalis, Inc.
Via Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Personalis Reports Second Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Personalis to Announce Second Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics
From Personalis, Inc.
Via Business Wire
Dr. Kenneth J. Widder Joins Personalis Board of Directors
From Personalis, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.